Company Overview
Snapshot
Founded in July 2025 by Hai Zaguri and Ron Bessler, FiBreath operates with 1–10 employees. The company has raised $9K across one funding round from one investor. In July 2025, FiBreath secured a grant from BizTEC.
Business overview
FiBreath is a Health Tech & Life Sciences company focused on addressing respiratory diseases. Operating in stealth mode, the company is developing a novel inhaled-therapy platform designed for deep-lung delivery and enhanced patient outcomes. FiBreath's business model centers on licensing its platform to pharmaceutical and inhaler manufacturers in exchange for royalties, serving the Americas, Asia, and Europe markets.
Log in to access full profile ›Company Intelligence Q&A
- What is FiBreath's primary focus?
- FiBreath is focused on developing a novel inhaled-therapy platform for deep-lung delivery to improve outcomes for asthma and COPD patients.
- When was FiBreath founded and by whom?
- FiBreath was founded in July 2025 by Hai Zaguri, who serves as CEO, and Ron Bessler, the CTO.
- What is FiBreath's business model?
- FiBreath plans to license its inhaled-therapy platform to leading pharmaceutical and inhaler manufacturers, generating revenue through royalties.
- What is the current product stage for FiBreath?
- FiBreath's next-gen inhaler platform is currently in the R&D stage. The company is operating in stealth mode, focusing on developing the technology for deep-lung delivery and enhanced patient outcomes.
- Which markets does FiBreath target?
- FiBreath targets global markets including the Americas, Central America, Asia, North America, Europe, and South America.